TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02386852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study subjects received, in a double blind fashion, placebo pills identical to the drug (drug 1-ginseng, group 1; drug 2-ginkgo biloba-group 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study subjects received, in a double blind fashion, placebo pills identical to the drug (drug 1-ginseng, group 1; drug 2-ginkgo biloba-group 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study subjects received, in a double blind fashion, placebo pills identical to the drug (drug 1-ginseng, group 1; drug 2-ginkgo biloba-group 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginseng
Description: The ginseng group received two capsules containing either 1000 mg or 500 mg of Panax Ginseng extract standardized to 3% of ginsenosides (GNC, USA) or similarly looking placebo capsules over a period of three days of testing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginseng
Description: The ginseng group received two capsules containing either 1000 mg or 500 mg of Panax Ginseng extract standardized to 3% of ginsenosides (GNC, USA) or similarly looking placebo capsules over a period of three days of testing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo Biloba
Description: The ginkgo group received two capsules containing either 240 mg or 120 mg of ginkgo biloba extract standardized to 24% ginkgo flavone glycosides and 6% terpene lactones (GBE24/6) or similarly looking placebo capsules over a period of three testing days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo Biloba
Description: The ginkgo group received two capsules containing either 240 mg or 120 mg of ginkgo biloba extract standardized to 24% ginkgo flavone glycosides and 6% terpene lactones (GBE24/6) or similarly looking placebo capsules over a period of three testing days.
Study: NCT00427908

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biolgicals' meningococcal vaccine 134612 (Nimenrix)
Description: One intramuscular dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mencevax™ ACWY
Description: One subcutaneous dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningitec™
Description: One intramuscular dose.
Study: NCT01763541

Intervention type: DRUG
Group type: OTHER
Intervention: leuprolide acetate
Description: Given to both arms to induce hypogonadism

Intervention type: DRUG
Group type: OTHER
Intervention: leuprolide acetate
Description: Given to both arms to induce hypogonadism

Intervention type: DRUG
Group type: OTHER
Intervention: Anastrozole
Description: Given to men to prevent conversion of administered testosterone to estradiol.
Study: NCT03444558

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Natural supplement containing chlorogenic acid and luteolin
Description: 50 eligible subjects will receive natural supplement as the oral pills at a fixed dose of 1 pill/day (450 mg/day) for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (without any active ingredients)
Description: 50 eligible subjects will receive placebo (without any active ingredients) at a fixed dose of 1 pill/day for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
Study: NCT02035540

Intervention type: OTHER
Intervention: Decellularized human valves
Study: NCT02842528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diagnostic Interview for Genetic Studies

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic Interview for Genetic Studies

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic Interview for Genetic Studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Informant Schedule and Criteria

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Informant Schedule and Criteria

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Informant Schedule and Criteria

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Temperament and Character Inventory

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Temperament and Character Inventory

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Temperament and Character Inventory

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Barratt Impulsiveness Scale

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Barratt Impulsiveness Scale

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Barratt Impulsiveness Scale

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wisconsin Card Sorting Test

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wisconsin Card Sorting Test

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wisconsin Card Sorting Test

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: blood sample withdrawn

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: blood sample withdrawn

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: blood sample withdrawn
Study: NCT03667768

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glass ionomer sealant

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Non-sealant (toothbrushing)
Study: NCT03055884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: active tDCS versus sham tDCS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: active tDCS versus sham tDCS

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Verbal paired-associate learning task
Description: with or without repeated retrieval practice

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Verbal paired-associate learning task
Description: with or without repeated retrieval practice

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Verbal paired-associate learning task
Description: with or without repeated retrieval practice

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Verbal paired-associate learning task
Description: with or without repeated retrieval practice
Study: NCT02979704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 45 patients will be treated with rosuvastatin at a dose of (5-10) mg orally once daily dose for 08 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 45 patients will be treated with atorvastatin at a dose of (10-20) mg orally once daily dose for 08 weeks
Study: NCT01007799

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin D placebo
Description: 12 weeks of placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 12 weeks supplementation based on serum vitamin D levels
Study: NCT02847325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC0058TA
Description: 50 mg AC0058TA 100 mg AC0058TA 200 mg AC0058TA 400 mg AC0058TA
Study: NCT02677428

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control condition will involve referrals to VA websites and represents enhanced treatment-as-usual. A Veteran who completes a Compensation examination ordinarily has no further treatment or referral as part of the Compensation examination. The information about benefits-related websites controls for having information available about benefits and receiving encouragement to pursue that information. The control condition involves being urged to explore links to three VA websites with Compensation \& Pension-related information: (a) the VBA website with links about VA disability compensation, (b) the VBA site with fact sheets about the different types of benefits available to Veterans, and (c) the VBA websites for the local C\&P office where issues pertaining to an individual Veteran's specific application are addressed.
Study: NCT04567277

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External ventricular drainage (EVD) conversion into ventriculo-peritoneal shunt (VPS)
Description: EVD in high grade SAH patients were converted into VPS with 7-10 days of EVD insertion
Study: NCT02847325

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Placebo capsules
Study: NCT05171322

Intervention type: DEVICE
Intervention: WARD
Description: The following monitoring devices are included in the WARD monitoring system (as intervention):~Isansys Life Touch patch: Measures heart rate (HR), respiratory rate (RR) and electrocardiogram (ECG)~Wearable, wireless Pulse Oximeter (Model 3150 WristOx from Nonin): Measures peripheral oxygen saturation of arterial hemoglobin (SpO2) and pulse rate (PR)~Blood pressure monitor (Meditech BlueBP-05): Measures BP every 30 minutes during daytime and every 60 minutes during the night~All included patients are set up with the monitoring devices after surgery when they are back at their ward (with a maximum of 24 hours postoperative). Afterwards they wear the devices for up to 5 days. All measurements are sent through bluetooth to a tablet serving as a gateway which in turn sends data to a central server where the algorithmic processing ensures.
Study: NCT01317563

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamins A, E, C & Selenium
Description: daily dose = Vitamin A 10000 IU (beta carotene), Vitamin E 400 IU, Vitamin C 1200mg, and Selenium 300mcg.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: total daily dose = 1200mg whey protein, 800mg microcrystalline cellulose
Study: NCT01190917

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: The CBT social skills curriculum is manualized and anchored in CBT strategies, such as problem identification, affective education, performance feedback, and weekly homework activities to facilitate generalization. The curriculum is a compilation of lessons targeting key social deficits in children with ASD, such as nonverbal communication, emotion recognition, and theory of mind. Structured teaching includes defining skills, breaking them down into simple, concrete steps, modeling the skill through role-play, and introducing a game or activity to practice the target skill. The approach to the parent group will be psychoeducational with a focus on reviewing target skills, rationale for teaching target skills, homework, progress or obstacles, and identifying strategies to promote generalization. Parent information handouts will be provided.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Play Therapy
Description: The social play group is manualized, led by a trained clinician and support staff, follows a specific routine, and contains a parent group component. Group leaders will follow participants' interests and suggestions for games. Group leaders utilize strategies such as reflective functioning statements on the child's behaviors to build emotion-focused play skills. The therapeutic setting incorporates play designed to encourage emotion-focused play including make-believe (dolls, houses), sensory (e.g. play-doh), and cooperative play (e.g. board games) toys. The approach to the parent group will be supportive rather than psychoeducational. Parents will set the agenda for discussion, facilitated by the group leader.
Study: NCT01140971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Vaginal application of 25 micrograms every 6 hours until cervical ripening reach Bishop 6 or more

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley
Description: After Foley introduction, every 6 hours vaginal exam was performed. The cases on Bishop score increase or occurred spontaneous exit of catheter or spontaneous labour had been initiated are considered success.The failure was adopted if after48 hours occurred no cervical modifications.
Study: NCT02578017

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile DOT
Description: Mobile DOT is a multi-dimensional tool that uses automated reminders, adherence feedback messages, incentives, and video observation of medication administration.
Study: NCT04511325

Intervention type: OTHER
Group type: OTHER
Intervention: Potato Regimen
Description: 100 grams cooked white russet potato with the skin

Intervention type: OTHER
Group type: OTHER
Intervention: Refined Grain Regimen
Description: 75 grams of cooked long-grain white rice
Study: NCT03795506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nocturnal Temperature controlled Laminar Airflow (TLA) Treatment
Description: 12 weeks of overnight treatment with active TLA device

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TLA Device
Description: 12 weeks of overnight use of placebo TLA device
Study: NCT02988700

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal hyperbaric bupivacaine 0.25mg/kg 0.5%
Description: The lumber puncture will be made in the lateral position at the L4-5 or L5-S1 interspace with a 25 G pencil point Quincke spinal needle with a short bevel and the orifice of the spinal needle will be turned cephalad.
Study: NCT00821717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject ® (Ferric carboxymaltose)
Description: Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit.~After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline (0.9%)
Description: During the correction phase, patients will receive the number of normal saline injections (4 mL weekly) corresponding to the calculated total iron dose needed according to the individual iron deficit. During the maintenance phase, placebo patients will receive 4 mL normal saline monthly.
Study: NCT01856452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the mixture including indocyanine green
Description: Sentinel lymph node biopsy using near-infrared imaging system and gamma probe detector for the mixture of indocyanine green, blue dye, and radioisotope during operation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: radioisotope
Description: Sentinel lymph node biopsy using gamma probe detector for radioisotope during operation
Study: NCT04670718

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography Probe
Description: Use of OCT probe for examination of gastrointestinal tract
Study: NCT00685906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6140
Description: 90 mg tablet taken by mouth 2 times a day for 21 days per cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel and Ethinyl Estradiol (Nordette®)
Description: 1 tablet taken by mouth once a day for 28 days per cycle
Study: NCT02988700

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: caudal plain bupivacaine 2.5mg/kg 0.25%
Description: The sacral hiatus between the sacral conru will be palpated. While inserting the 23-G needle at 45° to the skin in the midline, a distance give or pop will be felt as the needle passes the sacral ligament into the caudal space, the needle will be tilted more toward the skin surface and inserted 2-3mm deeper.
Study: NCT02806440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose naltrexone
Description: Active comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT02039934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: The intervention consists of 30 minute sessions of high-intensity interval training on a bicycle ergometer three times per week.~Training program: After 5 minutes of warm-up the subject cycles for 10 intervals of 60 s. at 90 % maximum effort separated 60 s at 20% maximum effort, based on a previously performed spiroergometry, followed by 5 minutes of cool-down.
Study: NCT00069264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389
Description: E7389 Dose-escalation starting at 0.25 mg/m\^2 intravenous on Days 1, 8, and 15 of a 28 day cycle.
Study: NCT02174757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inersan
Description: Probiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inersan
Description: Probiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Antibiotic
Study: NCT03428334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral roflumilast
Description: Roflumilast, a phosphodiesterase 4 (PDE4) inhibitor is approved worldwide (including Hong Kong) for treatment of severe chronic obstructive pulmonary disease (COPD) with frequent exacerbations. Roflumilast has been shown to have anti-inflammatory effect in patients with COPD, with significant reduction of sputum absolute neutrophil count, IL-8 and neutrophil elastase compared with placebo treatment. Roflumilast can also improve the lung function parameters in patients with COPD and reduce the rate of moderate-to-severe exacerbations.
Study: NCT04550078

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Description: Subjects receive a single-dose of 800 mg calcium as calcium carbonate provided in 6 capsules with a standardized breakfast served in the morning.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Permeate
Description: Subjects receive a single-dose of 800 mg milk calcium as calcium permeate provided in 6 capsules with a standardized breakfast served in the morning.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive a single-dose of 0 mg calcium as placebo with maltodextrin provided in 6 capsules with a standardized breakfast served in the morning.
Study: NCT03474796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye-tracking
Description: Visualisation of 4 photographic scenarios (surgical situations), questionnaire, eye-tracking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye-tracking
Description: Visualisation of 4 photographic scenarios (surgical situations), questionnaire, eye-tracking
Study: NCT01443169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1 - Treatment A: Controlled Release Pregabalin
Description: 330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1 - Treatment B: Controlled Release Pregabalin
Description: 330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
Study: NCT04259151

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric wheelchair with activated assistance module
Description: This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance

Intervention type: DEVICE
Group type: OTHER
Intervention: Electric wheelchair with assistance module not activated
Description: This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with no activated assistance
Study: NCT01443169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1 - Treatment C:Controlled Release Pregabalin
Description: 330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1 - Treatment D: Controlled Release Pregabalin
Description: 330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1 - Treatment E: Immediate Release Pregabalin
Description: 300 mg IR capsule administered in the evening in the fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2 - Treatment B: Controlled Release Pregabalin
Description: 330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2 - Treatment D: Controlled Release Pregabalin
Description: 330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2 - Treatment A: Controlled Release Pregabalin
Description: 330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
Study: NCT03760445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM201
Description: 2.5 mg and 10mg capsules, given orally